Milestone Pharmaceuticals Statistics
Want to see MIST full AI Analyst Report?
Milestone Pharmaceuticals (MIST) Stock Statistics & Valuation Metrics
Total Valuation
Milestone Pharmaceuticals has a market cap or net worth of $45.44M. The enterprise value is $120.40M.
- Market Cap
- $45.44M
- Enterprise Value
- $120.40M
Share Statistics
Milestone Pharmaceuticals has 124,498,695 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 124,498,695
- Owned by Insiders
- 0.88%
- Owned by Institutions
- 31.42%
Financial Efficiency
Milestone Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -62.00%.
- Return on Equity (ROE)
- -1.51
- Return on Assets (ROA)
- -0.56
- Return on Invested Capital (ROIC)
- -62.00%
- Return on Capital Employed (ROCE)
- -0.63
- Revenue Per Employee
- 40.68K
- Profits Per Employee
- -1.66M
- Employee Count
- 38
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.18
Valuation Ratios
The current PE Ratio of Milestone Pharmaceuticals is -0.58. Milestone Pharmaceuticals’s PEG ratio is -0.08.
- PE Ratio
- -0.58
- PS Ratio
- 10.16
- PB Ratio
- -9.81
- Price to FCF
- -0.71
- Price to Operating Cash Flow
- -0.80
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of 1.55M and earned -63.06M in profits. Earnings per share was -0.75.
- Revenue
- 1.55M
- Gross Profit
- 1.43M
- Operating Income
- -62.48M
- Pretax Income
- -63.40M
- Net Income
- -63.06M
- EBITDA
- -59.45M
- Earnings Per Share (EPS)
- -0.75
Cash Flow
In the last 12 months, operating cash flow was -76.12M and capital expenditures -85,222, giving a free cash flow of -76.16M billion.
- Operating Cash Flow
- -76.12M
- Free Cash Flow
- -76.16M
- Free Cash Flow per Share
- -0.54
Dividends & Yields
Milestone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -145.82%
- Earnings Yield
- -165.59%
Stock Price Statistics
- Beta
- 2.51
- 52-Week Price Change
- -82.20%
- 50-Day Moving Average
- 0.80
- 200-Day Moving Average
- 1.30
- Relative Strength Index (RSI)
- 23.65
- Average Volume (3m)
- 1.48M
Important Dates
Milestone Pharmaceuticals upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Milestone Pharmaceuticals as a current ratio of 8.01, with Debt / Equity ratio of 139.76%
- Current Ratio
- 8.01
- Quick Ratio
- 7.96
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- -16.28
Taxes
In the past 12 months, Milestone Pharmaceuticals has paid -345.00K in taxes.
- Income Tax
- -345.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Milestone Pharmaceuticals EV to EBITDA ratio is 0.37, with an EV/FCF ratio of 0.41.
- EV to Sales
- -5.90
- EV to EBITDA
- 0.37
- EV to Free Cash Flow
- 0.41
- EV to Operating Cash Flow
- 0.41
Balance Sheet
Milestone Pharmaceuticals has $145.35M in cash and marketable securities with $60.94M in debt, giving a net cash position of $84.42M billion.
- Cash & Marketable Securities
- $145.35M
- Total Debt
- $60.94M
- Net Cash
- $84.42M
- Net Cash Per Share
- $0.68
- Tangible Book Value Per Share
- -$0.04
Margins
Gross margin is 91.95%, with operating margin of -1728.44%, and net profit margin of -1844.80%.
- Gross Margin
- 91.95%
- Operating Margin
- -1728.44%
- Pretax Margin
- -1846.85%
- Net Profit Margin
- -1844.80%
- EBITDA Margin
- -1616.34%
- EBIT Margin
- -1620.18%
Analyst Forecast
The average price target for Milestone Pharmaceuticals is $4.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.33
- Price Target Upside
- 949.23% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 12.79%
Scores
- Smart Score
- 2
- AI Score
- 45

